CNIO - Transfiere

FORO INTERNACIONAL DE LA
INNOVACIÓN
INTERNATIONAL INNOVATION FORUM
13:00-14:00 h. Mesa redonda – Round table
LA TRANSFERENCIA DE CONOCIMIENTO EN LOS CENTROS DE
EXCELENCIA SEVERO OCHOA
THE TRANSFER OF KNOWLEDGE IN THE CENTRES OF EXCELLENCE
SEVERO OCHOA
Spanish National Cancer Research Centre
Spanish National Cancer Research Centre
Research centre with a focus in oncology that strives for
scientific excellence and translation of its knowledge and
technologies to the society

CNIO was first conceived in the 90`s as part of the Spanish Govertnment strategic
plans to build monographic excellence research centres (CNIO, CNIC…). Becomes
operational early 2000´s

CNIO is managed by a Public Fundation and funded in aprox 50% by public funds
(Ministry of Eonomy and Competitiveness).

Distinctive features of CNIO’s management:

Managed/evaluation under key performance criiteria and advised by an external
Advisory Board

Flexibility in Human Resource Management: employees are not civil servants
We study cancer…
…at the atomic level
…at the chromosomic and celullar level
Structural Biology and Biocomputing
Program
Alfonso Valencia
Molecular Oncology & Cancer Cell Biology Programs
Manuel Serrano & Erwin Wagner
…using state of the art facilities and biological models
Biotechnology Program
Fernando Peláez
We study human tumours…
…to improve diagnostics
…improve prevention & prognosis
…to find new therapeutic treatments
Human Genetics Program
Javier Benítez
Clinical Research Program. Manuel Hidalgo
& Experimental Therapeutics Program
Joaquín Pastor
Spanish National Cancer Research Centre (CNIO)
Excellence Indicators:
grants, papers, rankings …
International Ranking (2010-2014)
(> 500 instituions (258 Spain) - Scimago Oct. 2010-2014)
Amongst biomedicine institutes
Excellence with leadership
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Institution
Whitehead Institute for Biomedical Research
J. David Gladstone Institutes
Stowers Institute for Medical Research
Friedrich Miescher Institute for Biomedical Research
Cold Spring Harbor Laboratory
Salk Institute for Biological Studies
Scripps Research Institute
Buck Institute for Age Research
Pennington Biomedical Research Center
La Jolla Institute for Allergy & Immunology
Memorial Sloan-Kettering Cancer Center
Joslin Diabetes Center
Institute of Cancer Research
Harvard Pilgrim Health Care
Walter and Eliza Hall Institute of Medical Research
Dana Farber Cancer Institute
Centers for Disease Control and Prevention
Centro Nacional de Investigaciones Oncologicas
Centro de Regulacion Genomica
Centre de Recerca en Epidemiologia Ambiental
Country
USA
USA
USA
CHE
USA
USA
USA
USA
USA
USA
USA
USA
GBR
USA
AUS
USA
USA
ESP
ESP
ESP
Excellence
with
Leadership
100
82.49
71.97
68.06
65.06
65.02
63.12
61.07
58.22
57.96
57.88
57.77
53.85
53.4
52.15
49.22
49.03
48.96
48.5
48.39
“Severo Ochoa” Distinction
2011
Spanish National Cancer Research Centre
Translational activity:
tests, drugs, & patients
Spanish National Cancer Research Centre
Training & education:
Fellowships, courses & seminars
Spanish National Cancer Research Centre
Communication & dissemination:
Better known in Spain & in the World
Spanish National Cancer Research Centre
Philanthropy, donations:
Engaging society
Spanish National Cancer Research Centre
CNIO Technology Transfer:
We accelerate new diagnostics and
therapeutics into the market
Tech Transfer Office @ CNIO
Vision & Mission
be an inspiring office at the interface of bench - academia - industry, with the aim to
enable scientific knowledge generated at CNIO to make a positive impact on cancer
patient treatment
Strategic Objective: The direction of technology tranfer directs and coordinates activities
to reinforce the translational capacity, the scientific excellence for the benefit of the
National Health System, the society and contribute to sustainability of the centre
Specific Objectives
 Foster innovation culture, encourage risk taking
 Implement and maintain the highest standards in techtransfer activities
 Promote collaborative environment with particular focus on Industry
 Proactively Identify, evaluate, select and build a valorization strategy for the most
outstanding & transferable knowledge and technologies generated at CNIO
CNIO towards a “Comprenhensive Cancer Center”
 The Technology Transfer Office at CNIO leverages on the CNIO´s
excellent innovation microenvironment
Excellence
Research
Applied
Research
(ETP, BT)
i
n
n
o
v
a
t
i
o
n
# Excellence “Severo Ochoa”
# International Top Ranking (Scimago)
# diagnostics
# prevention
# treatments
[industry]
[industry]
# new drugs
# biomarkers
Technology Transfer Indicators: Patents
 Patents. Historically 55 families. 22 Active. 13 licenced (- 25%)
 Characteristics:

Mature portfolio

More than half of the portfolio is mantained by licensees & partners
National Phase
PCT
Priority
0
5
10
15
20
Technology Transfer Indicators: Industry collaborations
 Considerable of income increase ( ̴ 2 X ) from collaborative research with
industry/stakeholders.
2014: 4.7 Mio compromised in contracts (2-3 years)
Millones
Collaborative Research with companies
5
Epigenetic & signalling
4,715486
4,5
4
3,5
Frontier science & innovation
3
2,675406
2,535579
2,5
2
1,5
1,706681
1,425773
Avatars & animal models
1
0,5
0
2010
2011
2012
2013
2014
New therapeutic drugs
Technology Transfer Indicators: consolidating partnerships
 2014. Banco Santander y la Fundación Botín renew their support in technology
transfer matters. 3 Research groups receive support.
CNIO: 3 Investigadores
Innovation Culture: CNInnOtrain towards consolidation
Training scientists in management and bussines
administration. 22 Scientists have followed this
training in 3 years
Technology Transfer: commercialization
2013
 25
technologies in commercialization
 Net Royalty: 293.326 €
 20 inventores
2014
 The royalty income is expected to double
 Many small bits contribute to sustaninability
60000
Net Royalty per technology
50000
40000
30000
20000
10000
0
1
2
3
4
5
6
7
8
9
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Experimental Therapetucs Program (ETP) CNIO
Joaquin Pastor, Director del Programa de Terápias Experimentales
Experimental Therapeutics Program
External Advisory Board
Working
Group
target
Target Selection
Committee (*)
Target
Identification
Validation
Internal Project Core Team
HTS
Hit Identification
Generation
Hit
To Lead
Lead
Optimization
CNIO ETP Medicinal Chemistry Facilities
Pre-clinical
Development
FIH
Clinical
Phases
Licencing to Pharma
PI3K/
Onco
Available for licensing
PI3K/
Obesity
Interest in Licensing: 1Co (due diligence)
PIM &
PIM dual
ATR
License agreement (Mar 2013)
License agreement (Dec 2013)
CDK8
Available for partnership
Kinase
-VIB
(Partnered- Co-development)
TRF1
MASTL
Available for partnership/Licensing
Interest 1Co (co-development partnership, due diligence)
(*) M. Serrano, A. Valencia, E. Wagner, O. Fernández-Capetillo, M. Blasco, J. Benítez, M. Hidalgo, and M. Soengas
CNIO Tech Transfer: The Path
“caminante, no hay camino,
walker, there is no path,
23
se hace camino al andar.
the path is made when walking”
Antonio Machado
Industrial
Partnership
IDEAS
KNOWLEDGE
TECHNOLOGY
Venture
Philantropy
Innovation-CNIO
Venture
Capital,
Business
Angels
THANK YOU
Tech Transfer @CNIO
 Strengths
 Solid and excelent science produced at CNIO
 High capacities and competences within the research groups and
State of the art facilities and technology
 Favorable microenvironment: Basic, Translational and Applied Research
All under ONE roof, which favors high turn over of ideas and testing
 Weakneses
Youth, as an organization at research and at techtransfer in particular
and therefore unexperienced.
 Sourranded by an underdeveloped innovation ecosystem
Challenges
 Strive for excellence in Innovation (youth)
Support & Extended Network of Partners (ecosystem. RRHH)
Stay focus though ensuring a critical number of transferable projects
(RRHH; funding)